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Relaxin Family Member Insulin-Like Peptide 6 Ameliorates Cardiac
Fibrosis and Prevents Cardiac Remodeling in Murine Heart Failure
Models
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Background-—The insulin/insulin-like growth factor/relaxin family represents a group of structurally related but functionally
diverse proteins. The family member relaxin-2 has been evaluated in clinical trials for its efﬁcacy in the treatment of acute heart
failure. In this study, we assessed the role of insulin-like peptide 6 (INSL6), another member of this protein family, in murine heart
failure models using genetic loss-of-function and protein delivery methods.
Methods and Results-—Insl6-deﬁcient and wild-type (C57BL/6N) mice were administered angiotensin II or isoproterenol via
continuous infusion with an osmotic pump or via intraperitoneal injection once a day, respectively, for 2 weeks. In both models,
Insl6-knockout mice exhibited greater cardiac systolic dysfunction and left ventricular dilatation. Cardiac dysfunction in the Insl6-
knockout mice was associated with more extensive cardiac ﬁbrosis and greater expression of ﬁbrosis-associated genes. The
continuous infusion of chemically synthesized INSL6 signiﬁcantly attenuated left ventricular systolic dysfunction and cardiac
ﬁbrosis induced by isoproterenol infusion. Gene expression proﬁling suggests liver X receptor/retinoid X receptor signaling is
activated in the isoproterenol-challenged hearts treated with INSL6 protein.
Conclusions-—Endogenous Insl6 protein inhibits cardiac systolic dysfunction and cardiac ﬁbrosis in angiotensin II– and
isoproterenol-induced cardiac stress models. The administration of recombinant INSL6 protein could have utility for the treatment
of heart failure and cardiac ﬁbrosis. ( J Am Heart Assoc. 2018;7:e008441. DOI: 10.1161/JAHA.117.008441.)
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I nsulin-like peptide 6 (INSL6) is a hormone that belongs tothe insulin/insulin-like growth factor/relaxin peptide
superfamily. This family is characterized by a common
3-domain structure, and it plays crucial roles for metabolic
regulation, growth, and reproduction.1 Proteins in this family
are composed of a variable-length C-peptide that separates
A- and B-chain peptides and a signal peptide that is linked to a
B-chain peptide. The A- and B-chain peptides are relatively
invariant within the family, and they contain highly conserved
cysteine motifs. For most family members, mature hormones
are processed by proteolytic cleavage of C-peptide and signal
peptide, and the A- and B-chain peptides are connected by 2
interchain and 1 intrachain disulﬁde bonds.2,3
The relaxin/insulin-like peptide subfamily can be distin-
guished from the insulin/insulin-like growth factor peptides
by differences in their signaling mechanisms. Although insulin
and insulin-like growth factors use tyrosine kinase receptors,
most members of the relaxin/INSL subfamily are believed to
act on G-protein coupled receptors. Humans encode 7
relaxin/INSL proteins.2,4 They include ovarian relaxin, also
referred to as human relaxin-2, human relaxin-1, human
relaxin-3, and INSL3-6. The common ancestral gene appears
to be INSL3, producing other subfamily members through
evolutionary gene duplication mechanisms.2 The relaxin/INSL
From the Molecular Cardiology, Whitaker Cardiovascular Institute, Boston
University School of Medicine, Boston, MA (S.M., C.-L.W., S.Y., D.Z., P.-H.L.,
J.P.D., R.Y., B.J., K.W.); Center for Hematovascular Biology, Robert M. Berne
Cardiovascular Research Center, University of Virginia School of Medicine,
Charlottesville, VA (K.W.); Department of Chemistry, Indiana University,
Bloomington, IN (F.W., R.D.M.); Institute of Human Genetics, University Medical
Center G€ottingen, G€ottingen, Germany (I.M.A.); and New Frontier Science,
Takeda Pharmaceuticals International Co, Cambridge, MA (R.L., J.B.).
An accompanying Table S1 is available at http://jaha.ahajournals.org/content/
7/12/e008441/DC1/embed/inline-supplementary-material-1.pdf
*Dr Chia-Ling Wu and Dr Yoshida contributed equally to this work.
Correspondence to: Kenneth Walsh, PhD, Robert M. Berne Cardiovascular
Research Center, University of Virginia School of Medicine, 415 Lane Rd,
Box 801394, Ste 1010, Charlottesville, VA 22908. E-mail: kw9ar@virginia.edu
Received February 14, 2018; accepted April 25, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modiﬁcations or adaptations are made.
DOI: 10.1161/JAHA.117.008441 Journal of the American Heart Association 1
ORIGINAL RESEARCH
family proteins tend to be expressed in reproductive tissues,4
although relaxin-3 and INSL5 are highly expressed in nong-
onadal tissues, including the brain and gut, respectively.
Among the relaxin/INSL subfamily of proteins, relaxin-2
has been investigated to the greatest extent. Relaxin-2 was
originally identiﬁed as a peptide hormone that is elevated in
the ovary, placenta, and blood of pregnant females.5 Relaxin-2
is also expressed by the brain, kidney, and heart at lower
levels,6 where it is believed to have a fundamental role in
conditioning the reproductive organs and, perhaps, the
adaptation of the cardiovascular system to pregnancy.7–10
RLN2 gene expression is detected in human heart and is
downregulated in chronic heart failure.11 The relaxin family
peptide receptor 1, the receptor of human relaxin-2, is also
expressed in the reproductive organs as well as the heart,
arteries, kidney, lung, liver, and brain.6 On the basis of these
ﬁndings, the cardiovascular functions of relaxin-2 have been
explored in various models involving both female and male
animals. Several cardioprotective roles have been assigned
to relaxin-2, including vasodilatation, inhibition of ﬁbrosis,
inhibition of apoptosis, promotion of angiogenesis, and anti-
inﬂammation actions.12 Among these, the antiﬁbrotic actions
of relaxin-2 are commonly reported. For example, aging relaxin-
2–deﬁcient male mice display increased cardiac collagen
deposition and diastolic dysfunction.13 Relaxin-2 overexpres-
sion by systemic adenovirus delivery attenuates cardiac
collagen deposition in mice that overexpress the b2-adrenergic
receptor.14 Moreover, the antiﬁbrotic actions of recombinant
human relaxin-2 have been demonstrated in various cardiac
disease models, including myocardial infarction,15 diabetic
cardiomyopathy,16 and isoproterenol-induced cardiac injury,17
and in the spontaneously hypertensive rat.18
In contrast to relaxin-2, characterization of other members
of the relaxin/INSL subfamily is relatively limited. INSL6 is
predominantly expressed in testis, and homozygous INSL6-
deﬁcient male mice are infertile.19 Previously, we documented
the upregulation of INSL6 in the growing skeletal muscle of
mice that were genetically modiﬁed to express constitutively
active protein kinase B in this tissue.20,21 INSL6 expression is
also upregulated in mouse skeletal muscle after cardiotoxin-
induced skeletal muscle injury, and adenovirus-mediated
overexpression of INSL6 facilitates muscle regeneration in this
model.20 In a model of experimental autoimmune myositis,
INSL6-deﬁcient mice display greater motor function impair-
ment, whereas INSL6 overexpression protects muscle from
dysfunction.22
Although similar to relaxin-2 in overall structure, INSL6
shares only 43.1% homology to relaxin-2 at the amino acid level.
Despite this low level of homology, clinical and experimental
investigations into the cardioprotective roles of relaxin-2/
serelaxin led us to assess the role of INSL6 in murine cardiac
injury models. Using a genetic loss-of-function model and the
delivery of recombinant Insl6 protein, we ﬁnd that Insl6 protects
against pathological cardiac remodeling andﬁbrosis. These data
suggest that INSL6 and possibly other members of the relaxin/
Insl family can have utility in the treatment of heart failure.
Methods
The data, analytical methods, and study materials will be/
have been made available to other researchers for the
purposes of reproducing the results or replicating the
procedures. The authors declare that all supporting data are
available within the article and its online supplementary ﬁles.
Experimental Animals
Insl6-knockout mice were generated as previously described.19
Brieﬂy, exon 1 of the Insl6 gene is replaced by the PGK-
neomycin cassette. Insl6 knockoutmicewere backcrossedwith
C57BL/6N >6 times in the animal facility at Boston University
(Boston, MA), and a nearly homogeneous strain background
(99.5% for C57BL/6) was conﬁrmed by Jackson Laboratory’s
Genome Scanning Service. Because male infertility has been
reported,19 Insl6+/ heterozygous male and Insl6/ female
mice were used for breeding. Insl6+/+ male and Insl6+/+ female
mice of the same background were bred as control groups.
C57BL/6N mice were purchased from Charles River Laborato-
ries. All animal studies were performed with 8- to 12-week-old
male mice. Study protocols were approved by the Institutional
Animal Care and Use Committee at Boston University.
Cardiac Injury Models
The isoproterenol-induced cardiac injury model was used, as
previously reported.23–25 Brieﬂy, isoprenaline hydrochloride
Clinical Perspective
What Is New?
• Mice deﬁcient in insulin-like peptide 6 (INSL6), a member of
the relaxin protein family, exhibit greater cardiac patholog-
ical features after the continuous infusion of angiotensin II
or isoproterenol.
• Administration of a chemically synthesized INSL6 peptide
protects murine heart from pathological cardiac remodeling
induced by isoproterenol.
• Insl6/INSL6 functions in part through the modulation of
cardiac ﬁbrosis.
What Are the Clinical Implications?
• INSL6, as well as other members of the relaxin family of
proteins, may be useful for the treatment of heart failure.
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(I5627; Sigma-Aldrich) dissolved in sterile saline at 50 mg/mL
was ﬁltered via a 20-lm ﬁlter. Aliquots of stock solution were
stored in the dark in a20°C freezer. The working solution was
freshly prepared with diluting stock solution containing sterile
saline. Isoproterenol (50 mg/kg per day; total, 100 lL) was
injected IP once a day for 14 days. The control group received
same amount of sterile saline. The angiotensin II (AngII)–
induced cardiac injury model was performed, as previously
reported.26–31 Human AngII protein (A9525; Sigma-Aldrich)
was dissolved with sterile saline. The AngII solution (2 mg/kg
per day) was administrated to mice subcutaneously for
14 days via an ALZET osmotic pump (model 1002; Durect). A
pump with sterile saline was implanted in the control group. All
mice were euthanized at 14 days. Recombinant human INSL6
protein was chemically produced using ﬂuorenylmethyloxycar-
bonyl-based solid-phase peptide chemistry and a regioselec-
tive disulﬁde bond construction protocol, as previously
described.32 INSL6 protein (50–70 nmol/kg per day) was
infused into mice SC using an ALZET osmotic pump (model
2002; Durect). The osmotic pump with vehicle (pH 8.5,
ammonium bicarbonate) was implanted in the control group.
All isoproterenol model studies in Insl6-knockout and INSL6
protein were performed in a blinded manner by ≥2 experienced
researchers. Speciﬁcally, the assignment of mice to experi-
mental groups and pump preparation was performed by one
unblinded researcher, and a different blinded researcher
obtained data from each experimental group. Group identities
were revealed after all analyses were completed.
Echocardiography and Blood Pressure
Measurements
Cardiac function of mice was assessed at day 13 after
isoproterenol or AngII administration by echocardiography
using a Vevo2100 machine with a 550 probe and a Vevo770
machine using a 707B probe (VisualSonics). Mice were lightly
anesthetized with isoﬂurane. An examination was performed
with heart rate at 450 to 550 beats per minute, and we
excluded mice that were signiﬁcantly affected by anesthesia.
Left ventricular (LV) internal diastolic dimension and LV
internal systolic dimension were measured from M-mode
images obtained by LV short-axis view. LV systolic function
was assessed by fractional shortening (FS) and ejection
fraction (EF). FS was obtained from M-mode by short-axis
view, and EF was obtained from B-mode by tracing of LV long-
axis view. Except for the EF measurements, 3 measured
values per mouse were used for statistical analysis. Mouse
blood pressure was measured at 12 days after isoproterenol
or AngII administration by tail cuff method using BP-2000
Blood Pressure Analysis System (Visitech Systems, Inc). The
median systolic blood pressure was calculated from 15 to 20
measured values for each mouse.
Histological Features
Heart samples were obtained at 14 days after isoproterenol
or AngII administration or 11 days after coadministration of
recombinant INSL6 protein and isoproterenol. Cardiac ﬁbrosis
was assessed by Picrosirius Red staining, as previously
reported.33 Brieﬂy, parafﬁn-embedded hearts were sectioned
by microtome for a 6-lm thickness. The sections were
deparafﬁnized, rehydrated, and incubated with freshly pre-
pared Picrosirius Red staining buffer (1.2%/w picric acid in
water, 0.1%/w Fast Green FCF, and 0.1%/w Direct Red 80
solved in PBS) for 1 hour at room temperature. Then, sections
were washed with distilled water and dehydrated. The
sections were mounted by coverslip using Permount mounting
medium (Fisher Scientiﬁc). The images were produced by a
light microscope (BZ-9000; Keyence). Cardiac ﬁbrosis was
assessed from the 3 most severe images per mouse in the
isoproterenol model. Fibrosis in the AngII model was assessed
with whole heart sections to measure perivascular ﬁbrosis
and interstitial ﬁbrosis patterns. Fibrosis was quantiﬁed using
Photoshop software.
RNA Extraction and Analysis
Heart LV samples harvested at 14 days from the different
experimental groups were snap frozen. An RNeasy Lipid
Tissue Mini kit (Qiagen) was used to extract mRNA with a
Qiacube machine, according to the manufacturer’s protocol.
Alternatively, samples were homogenized in 1 mL of TRIzol
reagent with stainless steel beads using TissueLyser II (all
from Qiagen) and extracted, as described previously.34 The
concentration of RNA was measured using a NanoDrop 1000
(Thermo Scientiﬁc). Extracted RNA (1 lg) was reverse
Table 1. Primer Sequences
Gene Name Forward Primer Reverse Primer
nppa 50-AAG AAC CTG CTA
GAC CAC CTG-30
50-TGC TTC CTC AGT
CTG CTC AC-30
nppb 50-CAA GGC CTC ACA
AAA GAA CA-30
50-ATC CGA TCC GGT
CTA TCT TG-30
Tgfb1 50-GTG CGG CAG CTG
TAC ATT GAC TTT-30
50-TGT ACT GTG TGT
CCA GGC TCC AAA-30
Col1a1 50-GGG TCT AGA CAT
GTT CAG CTT TGT G-30
50-ACC CTT AGG CCA
TTG TGT ATG C-30
Col1a3 50-AGG CTG AAG GAA
ACA GCA AA-30
50-TAG TCT CAT TGC
CTT GCG TG-30
36b4 50-GCT CCA AGC AGA
TGC AGC A-30
50-CCG GAT GTG AGG
CAG CAG-30
18S 50-CTT AGA GGG ACA
AGT GGC G-30
50-GGA CAT CTA AGG
GCA TCA CA-30
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transcribed to cDNA by QuantiTect Reverse Transcription kit
(Qiagen), according to the manufacturer’s protocol. Real-time
quantitative reverse transcription–polymerase chain reaction
was performed by ViiA TM7 Real Time PCR system (Applied
Biosystems) with Power SYBR Green PCR Master Mix (Applied
Biosystems). The relative levels of transcript were determined
B 
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Figure 1. Exacerbated cardiac systolic dysfunction in insulin-like peptide 6–knockout (Insl6-KO) mice
in the angiotensin II (AngII) infusion model compared with wild type (WT). A, Timeline for AngII infusion
model for Insl6-KO (KO) mice and littermate control WT mice. B, Representative M-mode images of left
ventricle by echocardiography at 13 days of saline (Sham) or AngII infusion. C, Cardiac function and
morphological parameters by echocardiography measurements; left ventricular diastolic dimension
(LVDd), left ventricular systolic dimension (LVDs), fractional shortening (FS), and ejection fraction (EF)
are shown. D, Absolute wall thickness and relative wall thickness are calculated from echocardiogram
measurements. E, Relative transcript levels of Nppa and Nppb in hearts assessed by real-time
quantitative polymerase chain reaction. Error bars represent meanSD (n=12 for each mouse genotype
in sham group, n=16 for each mouse genotype in AngII group). BP indicates blood pressure. *P<0.05,
**P<0.005, ***P<0.001 indicate signiﬁcant differences between sham and AngII group in the same
mouse strain. #P<0.05, ##P<0.005, ###P<0.001 indicate signiﬁcant difference between WT and KO.
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by using D-D Cycle threshold methods. Each target gene level
was normalized by 18S and 36B4. Primer sequences are
shown in Table 1. For gene expression proﬁling, 3 pooled RNA
samples for sham, isoproterenol with vehicle, and isopro-
terenol with INSL6 protein were sent to the Boston University
core facility for processing. Brieﬂy, RNA samples were
ampliﬁed, labelled, and hybridized on Affymetrix mouse Gene
Expression Array 2.0, per the manufacturer’s instructions.
Microarray data processing for gene-level expression values
was performed, as previously described,35 and deposited into
the Minimum information about a microarray experiment
(MIAME)-compliant National Center for Biotechnology Infor-
mation Gene Expression Omnibus with accession number
GSE102612 (Reviewer Token: ezahmywmlvwprsr). Genes with
a fold change >1.5 or <1.5 by isoproterenol (sham versus
isoproterenol with vehicle) or INSL6 protein treatment
(isoproterenol with vehicle versus isoproterenol with INSL6)
were uploaded to Ingenuity Pathway Analysis (Qiagen) for
canonical pathway analysis and comparison analysis. Path-
ways with –log(Benjamini-Hochberg multiple testing correc-
tion P value) ≥10 and absolute Z score ≥1 were considered
signiﬁcantly enriched pathways.
Statistical Analysis
All results are presented as meanSD using GraphPad Prism
5 and 6 (GraphPad Software). Statistical analyses were
performed using SPSS Statistics 20 (IBM) and GraphPad
prisms. Distribution of data (data of normality) was analyzed
using a Shapiro-Wilk test. Then, data with a normal distribu-
tion were analyzed using parametric analysis. For treatment
and genotype effect comparison, 2-way ANOVA was per-
formed, and post hoc multiple comparison was performed by
Sidak’s test or Tukey’s test (Figures 1C through 1E, 2, 3B, 3C,
4C through 4E, 5B, and 5C, Tables 2 and 3). For 2-group
comparison, the unpaired t tests with Welch’s correction were
performed (Figures 6C through 6E, 7B, and 7C, Table 4).
P<0.05 was considered statistically signiﬁcant.
Results
Impaired Cardiac Systolic Function in Insl6-
Knockout Mice in the AngII Model
To investigate the role of endogenous INSL6 in a murine
model of heart failure, wild-type (WT) and Insl6-knockout mice
were infused with AngII or vehicle for 2 weeks (Figure 1A). In
the sham state, there were no signiﬁcant differences with
respect to body weight (BW), systolic blood pressure, or
cardiac function between WT and knockout mice (Table 2).
With AngII infusion, heart weight (HW) normalized to tibia
length (TL) or BW was signiﬁcantly increased in Insl6-
knockout mice compared with WT mice group (HW/TL,
P=0.043; and HW/BW, P=0.0019; Table 2). Similarly, the lung
weight (LW) of AngII-infused Insl6-knockout mice was signif-
icantly greater than that of AngII-infused WT mice (LW/TL,
P=0.043; and LW/BW, P=0.019; Table 2), indicative of lung
congestion.
Echocardiographic analysis showed that AngII infusion led
to signiﬁcant concentric hypertrophy in both strains (Fig-
ure 1B). Under these conditions, WT mice treated with AngII
maintained cardiac systolic function, as represented by lack
of changes in FS and EF that was accompanied by increased
wall thickness and reduced LV chamber size (Figure 1C and
1D). In contrast, Insl6-knockout mice infused with this dose
of AngII displayed exacerbated cardiac dysfunction com-
pared with WT mice treated with AngII (22.6% [P=0.001] and
16.5% [P=0.001] reductions in FS and EF, respectively)
(Figure 1C). This was accompanied by greater LV chamber
dilatation and reductions in wall thickness (Figure 1C and
1D). In histological analyses, cardiomyocyte cross-sectional
area was signiﬁcantly increased in AngII group compared
with sham group in WT mice, and this increase of
cardiomyocyte size was signiﬁcantly attenuated in Insl6-
knockout mice compared with WT mice (P=0.014), suggest-
ing chamber dilatation under these conditions (Figure 2). We
also investigated the expression of cardiac natriuretic
peptides that serve as biomarkers for predicting the onset
of heart failure.36 Although AngII infusion upregulated Nppa
and Nppb mRNA expression in hearts from both strains of
mice, Insl6-knockout mice treated with AngII showed
increases in Nppa and Nppb mRNA expression compared
with WT mice (P=0.0314 and 0.0408, respectively, when
performing unpaired t tests on the 2 AngII-infused groups)
(Figure 1E). Collectively, these data suggest that Insl6
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Figure 2. Decreased angiotensin II (AngII)–in-
duced cardiac myocyte (CM) hypertrophy in
insulin-like peptide 6–knockout (KO) mice. Relative
increase (fold change) of cross-sectional area of
CMs in left ventricle. The hearts were harvested at
day 14. Error bars represent meanSD (n=12 per
group). WT indicates wild type.
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Figure 3. Increased cardiac ﬁbrosis in insulin-like peptide 6–knockout (KO) mice in the
angiotensin II (AngII) infusion model compared with wild-type (WT) mice. A, Fibrosis of the
heart in the AngII model is shown by Picrosirius Red staining. Representative images of
ﬁbrosis in the entire heart section (top), left ventricle (middle), and perivascular area
(bottom). The scale bar indicates 1 mm (top), 100 lm (middle), and 200 lm (bottom). B,
Fibrosis quantiﬁcation for each categorized ﬁeld in heart histological features. C, Relative
transcript level of Tgfb1, Col1a1, and Col3a1 in hearts assessed by real-time quantitative
polymerase chain reaction. Error bars represent meanSD (n=12 for each WT and KO
experimental group in sham conditions, and n=16 for each experimental AngII condition).
*P<0.05, ***P<0.001 indicate signiﬁcant differences between sham and AngII group in
the same mouse strain. #P<0.05, ##P<0.005, ###P<0.001 indicate signiﬁcant difference
between WT and KO.
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deﬁciency exacerbates pathological cardiac remodeling in
response to continuous AngII stimulation.
Exacerbated Cardiac Fibrosis in AngII-Infused
Insl6-Knockout Mice
To investigate the role of INSL6 on ﬁbrosis associated with
cardiac dysfunction, sections of hearts from WT and Insl6-
knockout mice, treated with AngII or vehicle infusion for
2 weeks, were stained with Picrosirius Red and quantiﬁed.
AngII infusion induced signiﬁcant cardiac ﬁbrosis in WT mice
in the interstitium and perivascular area of the LV (P<0.0001
and P=0.0255, respectively; Figure 3A and 3B). Greater
AngII-induced ﬁbrosis was observed in the hearts of Insl6-
knockout mice compared with WT mice (P=0.0015,
P=0.0004, and P=0.0089, respectively; Figure 3A and 3B).
The expression of Tgfb1, a key mediator of ﬁbrosis, was also
signiﬁcantly increased in Insl6-knockout compared with WT
mice (P=0.0058; Figure 3C). Correspondingly, there was
signiﬁcant upregulation in Col1a1 and Col3a1 mRNA
expression in the Insl6-knockout hearts treated with AngII
compared with WT (P=0.042 and P=0.0066, respectively;
Figure 3C). Cytokine expression was analyzed because it is
widely recognized that inﬂammation triggers tissue ﬁbrosis.
There was a signiﬁcant increase in IL6 mRNA expression
level and a trend toward increase in Tnfa in Insl6-knockout
mice compared with WT mice (P<0.05 and P=0.149,
respectively) (data not shown). However, an increase in the
inﬁltration of inﬂammatory cells (lymphocytes and macro-
phage) in Insl6-knockout mice hearts was not detected by
real-time quantitative polymerase chain reaction and histo-
logical analysis (data not shown). Collectively, these results
indicate that endogenous INSL6 plays a central role in
limiting cardiac ﬁbrosis in the model of AngII-induced cardiac
dysfunction.
Isoproterenol-Induced LV Systolic Dysfunction Is
Exacerbated in Insl6-Knockout Mice
A moderate-dose isoproterenol administration to WT and
Insl6-knockout mice was used to investigate cardiac dysfunc-
tion and ﬁbrosis in a model that displays more uniform cardiac
ﬁbrosis than the AngII infusion model (Figure 4A). In WT mice,
this dose of isoproterenol (50 mg/kg per day IP) led to an
increase in HW (HW/TL and HW/BW; unpaired t test
P=0.0413 and P=0.0300, respectively; Table 3) but had little
or no effect on cardiac function (Figure 4B and 4C). In
contrast, Insl6-knockout mice displayed signiﬁcantly wors-
ened cardiac systolic function after treatment with isopro-
terenol. Speciﬁcally, Insl6-knockout hearts displayed a more
dilated LV systolic dimension (P=0.0306; Figure 4C), and
parameters for cardiac systolic function, FS and EF, were also
signiﬁcantly reduced in Insl6-knockout mice compared with
WT mice (P=0.0493 and P=0.0405, respectively; Figure 4C).
In isoproterenol-treated mice, a signiﬁcant upregulation in
Nppb mRNA level was observed in the Insl6-knockout strain
(P=0.0152) despite the lack of changes in wall thickness or
Nppa expression (Figure 4D and 4E).
Isoproterenol-Induced LV Interstitial Fibrosis Is
Exacerbated in Insl6-Knockout Mice
Compared with AngII, isoproterenol administration induced
a diffuse and more uniform pattern of interstitial LV ﬁbrosis
primarily in the endocardium of both WT and Insl6-knockout
mice (Figure 5A). Quantiﬁcation by Picrosirius Red staining
of sections of the LV revealed signiﬁcantly increased
isoproterenol-induced cardiac ﬁbrosis in Insl6-knockout
mice compared with WT mice (P=0.0073; Figure 5B).
Similarly, isoproterenol treatment led to signiﬁcant
increases in Tgfb1 and Col3a1 mRNA expression in Insl6-
knockout mice (P=0.0167 and P=0.0483, respectively;
Figure 5C), whereas a trend of increased Col1a1 mRNA
was observed in Insl6-knockout mice (unpaired t test
P=0.1148; Figure 5C).
Recombinant Human INSL6 Protein Protects the
Heart From Isoproterenol-Induced Cardiac
Systolic Dysfunction and Fibrosis
To investigate whether INSL6 protein protects against cardiac
remodeling, a recombinant human INSL6 protein formulation
(70 nmol/kg per day) was administered continuously via SC
osmotic pump in WT C57BL/6N male mice 2 days before the
initiation of isoproterenol treatment (Figure 6A). INSL6 pro-
tein treatment signiﬁcantly reduced LW (LW/TL and LW/BW,
P=0.011 and P=0.0034, respectively; Table 4). Isoproterenol-
induced changes in LV systolic and diastolic dimensions were
signiﬁcantly attenuated by INSL6 protein treatment compared
with vehicle control group (P=0.0236 and P=0.0068, respec-
tively; Figure 6B and 6C, left panel). Isoproterenol-induced LV
systolic dysfunction was also attenuated by INSL6 protein
treatment (P=0.0395 for FS and P=0.0391 for EF; Figure 6C,
right panel). Although there was no detectable effect on LV
wall thickness (Figure 6D), INSL6 protein treatment
signiﬁcantly attenuated isoproterenol-induced Nppb mRNA
expression compared with vehicle control (P=0.0104; Fig-
ure 6E).
The INSL6-treated group displayed signiﬁcantly attenuated
interstitial ﬁbrosis compared with the vehicle control group
(P=0.00473; Figure 7A and 7B). Correspondingly, INSL6
protein treatment resulted in a reduction of Tgfb1 mRNA
expression (P=0.0411) and trends toward reduction in Col1a1
and Col3a1 mRNA expression compared with the vehicle
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control condition (Figure 7C). Moreover, INSL6 protein
administration led to the upregulated expression of matrix
metalloproteinase 2 mRNA compared with vehicle control
(P=0.0003) (data not shown), suggesting that INSL6 protein
administration can also suppress cardiac ﬁbrosis by promot-
ing its degradation.
B
A
C
ED
Figure 4. Exacerbated left ventricular systolic dysfunction in insulin-like peptide 6–knockout (Insl6-KO)
mice in the isoproterenol (Iso) injection model compared with wild-type (WT) mice. A, Timeline for Iso-
induced cardiac remodeling in Insl6-KO (KO) mice and littermate control WT mice. B, Representative M-mode
images of left ventricle (LV) by echocardiography at 13 days of Iso injection. C, Cardiac function and
morphological parameters from echocardiography measurements; LV diastolic dimension (LVDd), LV systolic
dimension (LVDs), fractional shortening (FS), and ejection fraction (EF) are shown. D, Absolute wall thickness
and relative wall thickness are calculated from echocardiogram measurements. Echocardiographic
parameters were performed in triplicate for each mouse, except for the determination of EF. E, Relative
transcript levels of Nppa and Nppb in hearts assessed by real-time quantitative polymerase chain reaction.
Error bars represent meanSD (n=8, 6, 12, and 10 for WT-sham, KO-sham, WT-Iso, and KO-Iso, respectively).
BP indicates blood pressure. *P<0.05 indicates signiﬁcant differences between sham and isoproterenol
group in the same mouse strain. #P<0.05 indicates signiﬁcant difference between WT and KO.
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Transcriptome Signature of INSL6 Treatment in
Response to Isoproterenol-Induced Heart Failure
To develop a nonbiased assessment of gene regulatory
alterations associated with INSL6-mediated cardioprotection,
Affymetrix microarray transcriptome proﬁling was performed
on sham hearts, isoproterenol-challenged hearts treated with
vehicle, and isoproterenol-challenged hearts treated with
INSL6 protein. Principle component analysis showed that
both isoproterenol and INSL6 infusion administration had
signiﬁcant impacts in gene expression proﬁling in hearts
from C56BL/6N male mice. Isoproterenol administration
signiﬁcantly altered the gene expression proﬁle along the
Principle component 1 axis (ie, x axis on Figure 8A), which
contributes to 51% of the total gene expression variance.
INSL6 protein also signiﬁcantly alters the gene expression
along PC2 axis (ie, y axis on Figure 8A), which contributes to
49% of the total variance. Using a 1.5-fold expression
change as a cutoff, 455 genes were identiﬁed whose
expression was altered by isoproterenol (sham versus
isoproterenol) and 529 genes were identiﬁed whose expres-
sion was altered by INSL6 protein (isoproterenol versus
isoproterenol with INSL6 protein) (Figure 8B and 8C). Among
these, expression of 160 genes was altered by both
isoproterenol and INSL6 protein treatment, as shown by
the Venn diagram in Figure 8B. Of these 160 genes, a large
majority (ie, 147 genes) were regulated in an opposing
manner; 74 genes were upregulated by isoproterenol
challenge and downregulated by INSL6 protein treatment,
and 73 genes were downregulated by isoproterenol
A B
C
Figure 5. Advanced cardiac ﬁbrosis in insulin-like peptide 6–knockout (KO) mice in the isoproterenol (Iso)
model compared with wild-type (WT) mice. A, Heart sections stained by Picrosirius Red staining.
Representative images of interstitial left ventricular ﬁbrosis of endocardium are shown. B, Cardiac ﬁbrosis
area was quantiﬁed as pixel count. C, Relative transcript level of Tgfb1, Col1a1, and Col3a1 in hearts
assessed by real-time quantitative polymerase chain reaction. Error bars represent meanSD (n=8, 6, 12,
and 10 for WT-sham, KO-sham, WT-Iso, and KO-Iso, respectively). *P<0.05, **P<0.005 indicate signiﬁcant
differences between sham and isoproterenol group in the same mouse strain. #P<0.05, ##P<0.005 indicate
signiﬁcant differences between WT and KO.
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challenge and upregulated by INSL6 protein treatment. A list
of these genes can be found in Table S1.
To identify the pathways altered by INSL6 protein treat-
ment, canonical pathways represented by the differentially
expressed genes were identiﬁed using the literature-based
Ingenuity Pathway Analysis using a Z-score criterion ≥1.0
(Figure 8D). INSL6 protein treatment induced the activation of
genes associated with “liver X receptor (Lxr)/retinoid X
receptor (Rxr) signaling” (P<0.001, Z score=4.8) and down-
regulated genes classiﬁed as “lipopolysaccharide–interleukin-
1 mediated inhibition of RXR function” (P<0.001, Z
score=3.3). INSL6 treatment also modulated genes associ-
ated with “acute-phase response signaling” (33 upregulated
and 1 downregulated; P<0.001, Z score=1.8) and “comple-
ment system” (11 upregulated and 1 downregulated;
P<0.001, Z score=1.1).
Discussion
Heart failure is a progressive syndrome in which structural
and functional abnormalities of the heart lead to the
systemic failure to sufﬁciently deliver oxygen and nutrients
to metabolically active tissues.37 The treatment of heart
failure is challenging, involving prolonged in-hospital recov-
ery times and frequent readmission. It is predicted that the
prevalence of heart failure will increase 46% between 2012
and 2030.38 Thus, the development of novel treatments for
heart failure is warranted. Recently, a recombinant human
relaxin-2 formulation, referred to as serelaxin, has been
assessed as a potential therapeutic agent for acute heart
failure, with mixed success.39,40 In the phase 3 RELAX-AHF
(Serelaxin, Recombinant Human Relaxin-2, for Treatment of
Acute Heart Failure) trial of patients with acute heart
Table 2. Physiological Findings of WT and Insl6-Knockout Mice Induced With or Without AngII
Variable
Sham AngII
WT (n=12) Knockout (n=12)
P Value
Sham Group* WT (n=16) Knockout (n=16)
P Value
AngII Group*
BW, g 27.442.09 27.652.40 0.9642 24.482.01 24.431.97 0.9976
HW/TL, mg/mm† 5.870.59 5.690.55 0.8972 7.501.32 8.421.40 0.0430
HW/BW, mg/g† 4.910.51 4.710.41 0.8040 6.870.93 7.9031.10 0.0019
LW/TL, mg/mm‡ 7.141.42 6.811.45 0.8773 6.891.73 8.402.30 0.0430
LW/BW, mg/g‡ 5.941.00 5.610.99 0.8253 6.401.38 7.802.06 0.0190
Systolic BP, mm Hg 106.45.21 109.38.72 0.9746 156.310.41 156.211.64 >0.999
Data are shown as meanSD. AngII indicates angiotensin II; BP, blood pressure; BW, body weight; HW, heart weight; Insl6, insulin-like peptide 6; LW, lung weight; TL, tibia length; WT, wild
type.
*Ordinary 2-way ANOVA, Sidak’s multiple comparison test between WT and knockout in the same experimental group.
†HW is normalized by TL (HW/TL) or BW (HW/BW).
‡LW is normalized by TL (LW/TL) or BW (LW/BW).
Table 3. Organ Weight and BP at End Points: WT and Insl6-Knockout Mice Induced With or Without Isoproterenol Challenge
Variable
Sham Isoproterenol
WT (n=10) Knockout (n=6)
P Value
Sham Group* WT (n=14) Knockout (n=11)
P Value
Isoproterenol Group*
BW, g 27.300.870 27.330.954 0.9996 27.430.635 28.640.472 0.3554
HW/TL, mg/mm† 5.3780.164 5.4190.181 0.9925 5.8620.150 6.3990.332 0.1444
HW/BW, mg/g† 4.4830.146 4.5150.087 0.9930 4.9010.107 5.0700.279 0.7555
LW/TL, mg/mm‡ 6.0260.140 6.4910.191 0.8317 6.8550.125 8.1230.933 0.1260
LW/BW, mg/g‡ 5.0160.088 5.4350.257 0.8016 5.7400.065 6.4440.769 0.3713
Systolic BP, mm Hg 125.71.452 120.03.100 0.8499 117.47.115 114.48.28 0.9609
BP indicates blood pressure; BW, body weight; HW, heart weight; Insl6, insulin-like peptide 6; LW, lung weight; TL, tibia length; WT, wild type.
*Ordinary 2-way ANOVA, Sidak’s multiple comparison test between WT and knockout in the same experimental group.
†HW is normalized by TL (HW/TL) or BW (HW/BW).
‡LW is normalized by TL (LW/TL) or BW (LW/BW).
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failure, those who received a 16-hour infusion of serelaxin
showed improvements in biomarker expression patterns
reﬂecting cardiac, renal, and hepatic damage, and these
improvements correlated with reductions in all-cause
mortality by day 180.39,41 In animal models, serelaxin and
other formulations of recombinant relaxin-2 have been
shown to be protective in experimental models of cardiac
injury.15–18,42,43
Although the relaxin/INSL family displays limited sequence
homology between members, we examined whether INSL6
can affect cardiac remodeling in 2 pharmacological models of
murine heart failure. Part of our rationale for undertaking this
A
E
B
C
D
Figure 6. Recombinant insulin-like peptide 6 (INSL6) protein attenuated left ventricular (LV) systolic
dysfunction caused by isoproterenol (Iso) in wild-type (WT) mice. A, Timeline for administration of human
recombinant INSL6 protein (INSL6, 70 nmol/kg per day) or vehicle to Iso-injected C57BL/6N WT mice. B,
Representative M-mode images of LV by echocardiography at 10 days of Iso injection. C, Echocardiog-
raphy-measured LV diastolic dimension (LVDd), LV systolic dimension (LVDs), fractional shortening (FS),
and ejection fraction (EF) were shown. D, Absolute wall thickness and relative wall thickness are calculated
from echocardiogram measurements. Echocardiographic parameters were measured in triplicate for each
mouse, except for the determination of EF. E, Relative transcript levels of Nppa and Nppb in hearts assessed
by real-time quantitative polymerase chain reaction. Error bars represent meanSD (n=9 for Iso+vehicle,
n=8 for Iso+INSL6). BP indicates blood pressure; and KO, knockout. *P<0.05 indicates signiﬁcant
differences found between 2 groups.
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study was our prior observations that INSL6 had roles in
attenuating skeletal muscle injury.20,22 The present study
demonstrates that genetic INSL6 deﬁciency results in exac-
erbated LV systolic dysfunction in the AngII-infusion and
isoproterenol-treatment models of heart failure in mice. In
both models, cardiac ﬁbrosis was signiﬁcantly exacerbated by
INSL6 deﬁciency, suggesting antiﬁbrotic actions of INSL6 as a
component of the mechanism that limits the progression of
heart failure. Furthermore, the administration of human INSL6
protein to isoproterenol-treated WT mice was found to
signiﬁcantly improve LV systolic function and reduce cardiac
ﬁbrosis. In this study, we tested the efﬁcacy of a chemically
synthesized INSL6 protein produced by methods that yield
peptides joined by multiple disulﬁde bindings and retain
oxidation-sensitive residues.32 However, INSL6 may be sub-
jected to additional posttranslational modiﬁcations in vivo,
and additional investigations on the structure-function rela-
tionships of recombinant INSL6 proteins will need to be
deﬁned by future studies.
AngII is a potent smooth muscle mitogen and hypertrophic
agent that induces ﬁbrosis via activation of Angiotensin II
receptor type 1.44,45 Consistent with other studies under the
conditions of our assays,26 we ﬁnd that low doses of AngII
infusion in WT mice induced signiﬁcant cardiac hypertrophy
without causing signiﬁcant cardiac systolic failure. Isopro-
terenol acts on b-adrenergic receptors, resulting in increased
A
C
B
Figure 7. Recombinant insulin-like peptide 6 (INSL6) protein attenuated isoproterenol (Iso)–induced
cardiac ﬁbrosis in wild-type (WT) mice. A, Representative Picrosirius Red staining images for hearts from
C57BL6/N mice injected with 10 days of Iso with continuous vehicle or INSL6 protein administration.
Whole heart (top) and zoomed-in left ventricle (LV; bottom) images were shown. B, Cardiac ﬁbrosis area was
quantiﬁed by pixel count from zoomed-in LV images. C, Relative transcript level of Tgfb1, Col1a1, and
Col3a1 in hearts assessed by real-time quantitative polymerase chain reaction. Error bars represent
meanSD (n=9 for Iso+vehicle, n=8 for Iso+INSL6). KO indicates knockout. *P<0.05 indicates signiﬁcant
differences found between 2 groups.
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heart rate and cardiac overload.25,26 Consequently, increased
myocardium oxygen demand and stress results in cardiac
remodeling accompanied by myocardial necrosis, hypertro-
phy, and ﬁbrosis.25,44 In this study, we found that a moderate-
dose isoproterenol treatment resulted in LV systolic dysfunc-
tion and ﬁbrosis without inducing cardiac hypertrophy.
Notably, the patterns of ﬁbrosis differed between these 2
pharmacological models. AngII-induced cardiac ﬁbrosis was
focal and observed mainly in the perivascular area of coronary
arteries. On the other hand, isoproterenol-induced cardiac
ﬁbrosis was diffusely distributed throughout the LV endo-
cardium. In both models, INSL6 deﬁciency exacerbated
cardiac ﬁbrosis. Correspondingly, Insl6-knockout mice dis-
played increased expression of a key mediator of ﬁbrosis,
Tgfb1, and procollagen synthesis (ie, Col3a1) in both models.
These data demonstrate, for the ﬁrst time, the antiﬁbrotic
actions of Insl6. In comparison, the antiﬁbrosis effect of
relaxin-2 has been well characterized.46,47 Relaxin-2 knockout
mice display age-dependent increases in ﬁbrosis in the heart,
lung, kidney, and reproductive systems.46 At the cellular level,
relaxin-2 administration has been shown to counteract the
effects of transforming growth factor-b or AngII on ﬁbroblast
proliferation and differentiation, reduce collagen secretion,
and promote matrix metalloproteinase activities.48 Similarly,
we ﬁnd that recombinant INSL6 can inhibit AngII-induced
Cola1a transcript expression and suppress transcription of a
reporter gene from an Smad binding element in cultured
ﬁbroblast cell lines stimulated with transforming growth
factor-b (data not shown). Given the divergence in sequence
homology between INSL6 and relaxin-2, these results suggest
that antiﬁbrotic actions may be a general property shared by
the broader relaxin/INSL family members.
At baseline, Insl6-deﬁcient mice exhibit normal cardiac
function that is no different from WT mice. These ﬁndings are in
contrast with relaxin-2–deﬁcient mice that develop mild car-
diomyopathy characterized by increasedatrial weight andﬁbrosis
accompanied by impaired LV diastolicﬁllingwith age.13With both
AngII and isoproterenol administration, Insl6-knockout mice
displayed signiﬁcantly worse LV systolic function compared with
WT mice, as evidenced by increased LV internal systolic
dimension and reduced FS and EF. Increased or trends of
increased expression of the cardiac natriuretic peptides, Nppa
andNppb, were alsodetected in the Insl6-knockoutmice. Relaxin-
2 serves as a vasodilator of coronary blood vessels in pregnancy
andheart failure, and this is thought tobemediatedbystimulating
natriuretic peptide A secretion49 and inhibiting endothelin-1
production.50 Because INSL6 deﬁciency and supplementation
showed mixed results on Nppa transcript level in both models,
these data suggest that INSL6may act throughmechanisms that
differ from, as well as mechanisms that are similar to, relaxin-2.
At the molecular level, relaxin-2/serelaxin binds to the G-
protein–coupled receptor relaxin family peptide receptor 1
and signals via the activation of cAMP. In turn, this is reported
to upregulate vascular endothelin B receptor, nitric oxide, and
vascular endothelial growth factor production, resulting in
decreased vascular resistance and increased cardiac
output.12,51 In contrast, INSL6, however, does not bind to
relaxin family peptide receptor 1 nor activate cAMP (data not
shown). Furthermore, the mechanisms of INSL6 action have
received little attention, and nothing is known about how this
protein confers cardiac protection. To begin to address this
issue, unbiased gene proﬁling was performed on isopro-
terenol-challenged mice that were treated with INSL6 protein
or vehicle (Figure 8). This analysis revealed that INSL6 protein
treatment contributes to signiﬁcant transcriptomic changes in
hearts that are challenged by isoproterenol infusion. Among
the dysregulated genes attributable to isoproterenol chal-
lenge, 35% (n=160) genes were also altered by INSL6 protein
treatment. Among those altered by both isoproterenol and
INSL6 effect on isoproterenol, most of these genes (91.8%)
were altered in an opposing manner. We thus focused on the
signaling pathways enriched by INSL6 protein treatment on
isoproterenol-challenged heart using Ingenuity Knowledge-
base. The LXR/RXR signaling pathway is one of the enriched
pathways affected by INSL6 protein treatment (Figure 8D).
LXRs a and b belong to the nuclear receptor superfamily of
ligand-activated transcription factors. It heterodimerizes with
RXR and binds to an LXR response element in the regulatory
regions of target genes.52,53 On binding of cholesterol and
oxysterol metabolites, LXR/RXR heterodimer undergoes a
conformational change that transactivates target gene
expression. Several lines of evidence suggest that LXR/RXR
are important cardiac transcriptional regulators of LV
remodeling.54 For instance, cardiac-speciﬁc LXR a transgenic
mice have been shown to be protected from AngII or transverse
aortic construction–induced LV hypertrophy, cardiac function,
Table 4. Organ Weight and BP at the Terminal End Point:
C57BL/6 WT Mice Treated With Isoproterenol and
Recombinant INSL6 Protein or Vehicle
Variable
Isoproterenol
Vehicle (n=8) INSL6 (n=9) P Value*
BW, g 29.000.5774 29.380.6529 0.6725
HW/TL, mg/mm† 6.2810.1688 6.1040.1297 0.4130
HW/BW, mg/g† 4.8990.1015 4.6790.0729 0.0936
LW/TL, mg/mm‡ 7.0240.1883 6.3190.157 0.0110
LW/BW, mg/g‡ 5.490.1737 4.8420.0857 0.0034
Systolic BP, mm Hg 111.62.511 112.84.221 0.8163
BP indicates blood pressure; BW, body weight; HW, heart weight; INSL6, insulin-like
peptide 6; LW, lung weight; TL, tibia length; WT, wild type.
*Unpaired t test, 2 tailed.
†HW is normalized by TL (HW/TL) or BW (HW/BW).
‡LW is normalized by TL (LW/TL) or BW (LW/BW).
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and ﬁbrosis.52 In WT mice, LXR agonist administration atten-
uated cardiac hypertrophy, systolic dysfunction, and ﬁbrosis
induced by transverse aortic construction.55
At the cellular level, LXRs have been shown to attenuate
hypertrophy in neonatal cardiomyocyte via improved meta-
bolic substrate use, downregulation of collagen synthesis, and
proﬁbrotic gene expression in cardiac ﬁbroblasts55; and they
have reduced apoptosis by inhibition of caspase-3 protein
expression.56 Analysis of the gene proﬁling data revealed that
the expression of cholesterol 7a-hydroxylase (Cyp7a), a target
gene activated by LxRa,57 was signiﬁcantly increased by 3.3-
fold in INSL6-treated mouse hearts compared with nontreated
mouse hearts subjected to isoproterenol insult.
Overexpression of the Cyp7a1 in cultured mouse macro-
phages has been shown to enzymatically convert cholesterol
to 7a-hydroxy-cholesterol, thus inducing cholesterol efﬂux.58
Cyp7a-induced cholesterol efﬂux in macrophages can be
further enhanced by apolipoprotein A-I (Apoa1). Interestingly,
INSL6 treatment signiﬁcantly increased Apoa1 expression by
4.6-fold as well as other members in the family, such as
ApoC2, ApoC3, Apoe, and Apoh (1.5-, 4.2-, 1.6-, and 2.7-fold,
respectively). In related studies, we found that INSL6
administration upregulated expression of several LXR/RXR
target genes in isoproterenol-treated heart, including Scd1
and Abca1, that control cholesterol and fatty acid homeosta-
sis (data not shown). Thus, it is tempting to speculate that
BA
C D
Figure 8. Global gene expression analysis for hearts from C57BL6/N mice treated with or without
recombinant insulin-like peptide 6 (INSL6) protein in isoproterenol (Iso) model. Three heart samples
were pooled and proﬁled by Affymetrix Mouse Gene 2.0ST array. A, Principle component analysis of
global gene expression in hearts from saline-injected mice (Sham, open circle), Iso-injected and vehicle-
administrated mice (Iso+vehicle, ﬁlled circle), and Iso-injected and recombinant INSL6 protein–
administrated mice (Iso+INSL6, triangle). B, Venn diagram depicts the number of differentially
expressed genes that were altered by Iso injection (dotted circle, comparison between Sham and
Iso+vehicle group) alone, by recombinant INSL6 protein administration (solid line circle, comparison
between Iso+vehicle and Iso+INSL6 group) alone, or by both (overlapped area between dotted and solid
line circle). Differentially expressed genes were deﬁned as a fold change >1.5-fold between 2 groups.
C, Histogram depicts the number of upregulated and downregulated genes with fold change >1.5-fold.
D, Top 4 enriched canonical signaling pathways in genes differentially expressed by INSL6 protein on
Iso-treated heart. A multiple-testing corrected P value was calculated using the Benjamini-Hochberg
method to control the rate of false discoveries. The ratio value represents the number of
molecules that belong to the Ingenuity pathway analysis database-deﬁned pathway. Z score predicts
activation or repression of pathway. IL-1 indicates interleukin-1; LPS, lipopolysaccharide; LXR, liver X
receptor; and RXR, retinoid X receptor.
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INSL6 mediates its cardioprotective actions via changes in
metabolite use through regulation of LXR/RXR signaling, but
further studies are needed to determine the causal role of
LXR/RXR in INSL6-mediated cardioprotection.
Conclusion
Endogenous INSL6 protects heart from adverse cardiac
remodeling and ﬁbrosis induced by isoproterenol or AngII
administration to mice. Recombinant human INSL6 protein
protected WT mice from isoproterenol-induced dysfunction
and ﬁbrosis. These data suggest that INSL6 and perhaps
other members of the relaxin/INSL family have therapeutic
potential in the treatment of heart failure.
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SUPPLEMENTAL MATERIAL 
Table S1. Transcriptome profiling results for wild type mice receiving sham, Iso, 
or Iso+INSL6 treatments (see following pages).  
Brainarray	
probeset	ID
Mouse	
Entrez	Gene	
ID
Human	
Entrez	Gene	
ID Symbol Description GO	Term(s) KEGG	Pathway(s)
Iso
	v
s	c
on
tr
ol
Iso
+I
ns
l6
	v
s	I
so
23968_at 23968 126206 Nlrp5 NLR	family,	pyrin	domain	containing	5 GO:0000166:	nucleotide	binding,	GO:0001701: in utero embryonic development, GO:0005515: protein binding, GO:0005524: ATP binding, GO:0005634: nucleus, GO:0005730: nucleolus, GO:0005737: cytoplasm, GO:0005739: mitochondrion, GO:0005829: cytosol, GO:0005938: cell cortex, GO:0007566: embryo implantation, GO:0009566: fertilization, GO:0009887: organ morphogenesis, GO:0031647: regulation of protein stability, GO:0043234: protein complex, GO:0043487: regulation of RNA stability, GO:0043623: cellular protein complex assembly, GO:0045179: apical cortex3.67 -2.03
100043617_at 100043617 Gm4553 predicted	gene	4553 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0005882: intermediate filament, GO:0008150: biological_process3.16 -1.58
114671_at 114671 4930444G20Rik RIKEN	cDNA	4930444G20	gene GO:0003674:	molecular_function, GO:0005575: cellular_component, GO:0008150: biological_process03013:	RNA	transport,	04310: Wnt	signaling pathway2.82 -3.04
100502992_at 100502992 Gm19491 predicted	gene,	19491 2.64 -1.78
669291_at 669291 Gm15363 predicted	gene	15363 2.62 -1.60
20005_at 20005 6133 Rpl9 ribosomal	protein	L9 GO:0003735:	structural constituent	of ribosome, GO:0005730: nucleolus, GO:0005737: cytoplasm, GO:0006412: translation, GO:0022625: cytosolic large ribosomal subunit, GO:0022625: cytosolic large ribosomal subunit03010:	Ribos me 2.58 -2.25
18346_at 18346 Olfr47 olfactory	receptor	47 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction2.49 2.56
436479_at 436479 Trav9-2 T	cell	receptor	alpha	variable	9-2 2.47 -2.75
620018_at 620018 Gm6124 predicted	gene	6124 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process2.38 -1.92
74271_at 74271 347541 Mageb5 melanoma	antigen,	family	B,	5 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process2.38 -2.26
100039315_at 100039315 Gm10436 predicted	gene	10436 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process2.35 -1.65
545655_at 545655 Gm13287 predicted	gene	13287 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process2.33 -1.87
668558_at 668558 Gm9241 predicted	gene	9241 2.25 -1.64
100316681_at 100316681 Mir1900 microRNA	1900 2.25 -1.80
243302_at 243302 Gm4963 predicted	gene	4963 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process2.19 -1.51
675440_at 675440 Gm13430 predicted	gene	13430 2.13 -1.65
634104_at 634104 121275 Olfr287 olfactory	receptor	287 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction2.09 -1.58
20091_at 20091 Rps3a ribosomal	protein	S3A GO:0003735:	structural constituent	of ribosome, GO:0005515: protein binding, GO:0005622: intracellular, GO:0005634: nucleus, GO:0005730: nucleolus, GO:0005737: cytoplasm, GO:0005829: cytosol, GO:0005840: ribosome, GO:0006412: translation, GO:0006917: induction of apoptosis, GO:0022627: cytosolic small ribosomal subunit, GO:0030154: cell differentiation, GO:0030529: ribonucleoprotein complex03010:	Ribos me 2.07 -2.07
100628603_at 100628603 Mir5134 microRNA	5134 2.07 -2.50
634834_at 634834 Gm11821 predicted	gene	11821 2.06 -2.56
233001_at 233001 Nlrp9a NLR	family,	pyrin	domain	containing	9A GO:0000166:	nucleotide	binding,	GO:0003674: molecular_function, GO:0005524: ATP binding, GO:0005575: cellular_component, GO:0005737: cytoplasm, GO:0008150: biological_process2.06 -1.68
624681_at 624681 Btnl6 butyrophilin-like	6 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process, GO:0016020: membrane, GO:0016021: integral to membrane2.00 -2.00
258490_at 258490 Olfr492 olfactory	receptor	492 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0005886: plasma	membrane, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0050896: response to stimulus, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction2.00 -1.65
238412_at 238412 Ighv2-3 immunoglobulin	heavy	variable	2-3 1.99 -1.86
544923_at 544923 Gm11397 predicted	gene	11397 GO:0004867:	serine-type endopeptidase inhibitor activity, GO:0005737: cytoplasm, GO:0010951: negative regulation of endopeptidase activity, GO:0030162: regulation of proteolysis05146:	Amoebiasis 1.98 -1.64
20716_at 20716 12 Serpina3n serine	(or	cysteine)	peptidase	inhibitor,	clade	A,	member	3N GO:0004867:	serine-type	endopeptidase	inhibitor activity, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0010951: negative regulation of endopeptidase activity, GO:0030162: regulation of proteolysis, GO:0034097: response to cytokine stimulus, GO:0043434: response to peptide hormone stimulus1.95 1.8
100502978_at 100502978 Gm19484 predicted	gene,	19484 1.94 -2.28
258036_at 258036 81050 Olfr198 olfactory	receptor	198 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction1.92 -2.01
258387_at 258387 254879 Olfr720 olfactory	receptor	720 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction1.91 -1.56
100504429_at 100504429 474343,544664930408F14Rik RIKEN	cDNA	4930408F14	gene GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.87 -1.57
17138_at 17138 Magea2 melanoma	antigen,	family	A,	2 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.85 -1.65
624512_at 624512 Vmn2r33 vomeronasal	2,	receptor33 GO:0003674:	molecular_function,	GO:0004871: signal transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0005575: cellular_component, GO:0005886: plasma	membrane, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0008150: biological_process, GO:0016020: membrane, GO:0016021: integral to membrane1.84 -1.99
434759_at 434759 Rhox4c reproductive	homeobox	4C GO:0003677:	DNA	binding,	GO:0005575:	cellular_component, GO:0005634: nucleus, GO:0008150: biological_process1.83 -1.60
100039895_at 100039895 Gm2479 predicted	gene	2479 1.83 -2.34
100504034_at 100504034 Gm20024 predicted	gene,	20024 1.81 -2.97
fold	changes
100862359_at 100862359 LOC100862359 disks	large	homolog	5-like 1.81 1.99
16665_at 16665 3866 Krt15 keratin	15 GO:0005198:	structural	molecule	activity,	GO:0005882: intermediate filament1.79 -1.79
259111_at 259111 Olfr974 olfactory	receptor	974 GO:0004984:	olfactory	receptor activity, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactor 	transduction1.76 -1.63
100041194_at 100041194 113146 Ahnak2 AHNAK	nucleoprotein	2 GO:0003674:	molecular_function,	GO:0003676: nucleic acid binding, GO:0005575: cellular_component, GO:0008150: biological_process1.76 1.56
246792_at 246792 Obox2 oocyte	specific	homeobox	2 GO:0003677:	DNA	binding,	GO:0005575:	cellular_component, GO:0005634: nucleus, GO:0008150: biological_process1.75 -3.36
20646_at 20646 6638 Snrpn small	nuclear	ribonucleoprotein	N GO:0003723:	RNA	binding,	GO:0005634:	nucleus, GO:0005685: U1 snRNP, GO:0005686: U2 snRNP, GO:0030529: ribonucleoprotein complex1.74 -2.07
19866_at 19866 Rnu7 U7	small	nuclear	RNA GO:0006396:	RNA	processing 1.74 -4.43
664987_at 664987 Gm14393 predicted	gene	14393 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.72 -1.94
432825_at 432825 Gm5458 predicted	gene	5458 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.72 -1.55
625558_at 625558 Gm6600 predicted	gene	6600 1.71 1.59
55990_at 55990 2327 Fmo2 flavin	containing	monooxygenase	2 GO:0004497:	monooxygenase activity, GO:0004499: N,N-dimethylaniline monooxygenase activity, GO:0005783: endoplasmic reticulum, GO:0006082: organic acid metabolic process, GO:0006739: NADP metabolic process, GO:0006805: xenobiotic metabolic process, GO:0009404: toxin metabolic process, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0016491: oxidoreductase activity, GO:0017144: drug metabolic process, GO:0031227: intrinsic to endoplasmic reticulum membrane, GO:0043231: intracellular membrane-bounded organelle, GO:0050660: flavin adenine dinucleotide binding, GO:0050661: NADP binding, GO:0055114: oxidation-reduction process, GO:0070995: NADPH	oxidation, GO:0072592: oxygen metabolic process00982:	Drug	metabolism - cytochrome P4501.68 1.50
20753_at 20753 6698 Sprr1a small	proline-rich	protein	1A GO:0001533:	cornified	envelope,	GO:0005198: structural molecule activity, GO:0005737: cytoplasm, GO:0018149: peptide cross-linking, GO:0030216: keratinocyte differentiation, GO:0030674: protein binding, bridging, GO:0031424: keratinization, GO:0071944: cell periphery1.68 2.17
319269_at 319269 A130040M12Rik RIKEN	cDNA	A130040M12	gene 1.67 -1.67
100039123_at 100039123 Gm14295 predicted	gene	14295 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.66 -1.62
384732_at 384732 120776 Gm10081 predicted	gene	10081 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.65 -1.65
258281_at 258281 Olfr780 olfactory	receptor	780 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction1.64 -1.80
17932_at 17932 4661 Myt1 myelin	transcription	factor	1 GO:0003677:	DNA	binding,	GO:0003700:	sequence-specific DNA binding transcription factor activity, GO:0005515: protein binding, GO:0005634: nucleus, GO:0006351: transcription, DNA-dependent, GO:0006355: regulation of transcription, DNA-dependent, GO:0007275: multicellular organismal development, GO:0007399: nervous system development, GO:0008270: zinc ion binding, GO:0030154: cell differentiation, GO:0046872: metal ion binding1.64 -1.64
11522_at 11522 126 Adh1 alcohol	dehydrogenase	1	(class	I) GO:0000166:	nucleotide binding, GO:0001523: retinoid metabolic process, GO:0004022: alcohol dehydrogenase (NAD) activity, GO:0004022: alcohol dehydrogenase (NAD) activity, GO:0004022: alcohol dehydrogenase (NAD) activity, GO:0004745: retinol dehydrogenase activity, GO:0005622: intracellular, GO:0005737: cytoplasm, GO:0005739: mitochondrion, GO:0005829: cytosol, GO:0006068: ethanol catabolic process, GO:0006068: ethanol catabolic process, GO:0006069: ethanol oxidation, GO:0008144: drug binding, GO:0008270: zinc ion binding, GO:0016491: oxidoreductase activity, GO:0032526: response to retinoic acid, GO:0033574: response to testosterone stimulus, GO:0035276: ethanol binding, GO:0042572: retinol metabolic process, GO:0042572: retinol metabolic process, GO:0042573: retinoic acid metabolic process, GO:0042573: retinoic acid metabolic process, GO:0042803: protein homodimerization activity, GO:0046186: acetaldehyde biosynthetic process, GO:0046872: metal ion binding, GO:0048149: behavioral response to ethanol, GO:00400010:	Glycolysis	/	Gluconeogenesis, 00071: Fatty acid metabolism, 00350: Tyrosin metabolism, 00830: Retinol metabolism, 00980: Metabolism of xenobiotics by cytochrome P450, 00982: Drug metabolism - cytochrome P450, 01100: Metabolic p thwa s1.64 3.00
258958_at 258958 Olfr525 olfactory	receptor	525 GO:0004871:	signal	transducer	activity,	GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell1.64 -1.64
319187_at 319187 8342 Hist1h2bn histone	cluster	1,	H2bn GO:0003674:	molecular_function, GO:0005575: cellular_component, GO:0008150: biological_process05322:	Systemic	lupus	erythematosus1.62 -1.62
434794_at 434794 Xlr4a X-linked	lymphocyte-regulated	4A GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.61 -1.81
66760_at 66760 4933425H06Rik RIKEN	cDNA	4933425H06	gene 1.60 -1.60
74399_at 74399 4933403O03Rik RIKEN	cDNA	4933403O03	gene 1.60 -1.60
15078_at 15078 3020,3021 H3f3a H3	histone,	family	3A GO:0001740:	Barr	body05322:	Systemic	lupus	erythematosus1.59 -1.59
229550_at 229550 9130204L05Rik RIKEN	cDNA	9130204L05	gene GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.59 -1.54
381058_at 381058 54346 Unc93a unc-93	homolog	A	(C.	elegans) GO:0003674:	molecular_function,	GO:0005886: plasma	membrane, GO:0008150: biological_process, GO:0016020: membrane, GO:0016021: integral to membrane1.58 -2.08
268449_at 268449 Rpl23a ribosomal	protein	L23A GO:0003674:	molecular_function03010:	Ribosome 1.57 -2.27
723957_at 723957 Mir194-2 microRNA	194-2 GO:0071222:	cellular	response	to	lipopolysaccharide, GO:0071230: cellular response to amino acid stimulus1.57 -2.08
258293_at 258293 Olfr437 olfactory	receptor	437 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction1.57 -2.54
268709_at 268709 11170 Fam107a family	with	sequence	similarity	107,	member	A GO:0001558:	regulation	of	cell	growth,	GO:0003674: molecular_function, GO:0005634: nucleus1.56 1.68
211135_at 211135 D130040H23Rik RIKEN	cDNA	D130040H23	gene GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.56 -1.56
751548_at 751548 Mir713 microRNA	713 1.56 -1.78
668349_at 668349 Gm9119 predicted	pseudogene	9119 1.56 -2.32
723974_at 723974 Mir500 microRNA	500 1.56 -1.56
100503583_at 100503583 100861412 Fsbp fibrinogen	silencer	binding	protein GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.56 -1.74
258513_at 258513 Olfr536 olfactory	receptor	536 GO:0004984:	olfactory	receptor activity, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactor 	transduction1.55 -1.55
666107_at 666107 Gm14623 predicted	gene	14623 1.55 -1.81
360220_at 360220 Speer4d spermatogenesis	associated	glutamate	(E)-rich	protein	4d GO:0003674:	molecular_function,	GO:0005634: nucleus, GO:0008150: biological_process1.55 -2.7
18424_at 18424 5015 Otx2 orthodenticle	homolog	2	(Drosophila) GO:0001077:	RNA	polymerase	II	core	promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, GO:0001708: cell fate specification, GO:0003677: DNA binding, GO:0005515: protein binding, GO:0005634: nucleus, GO:0005634: nucleus, GO:0005737: cytoplasm, GO:0006357: regulation of transcription from RNA polymerase II	promoter, GO:0006461: protein complex assembly, GO:0007411: axon guidance, GO:0007417: central nervous system development, GO:0007492: endoderm development, GO:0009887: organ morphogenesis, GO:0009952: anterior/posterior pattern specification, GO:0009952: anterior/posterior pattern specification, GO:0009953: dorsal/ventral pattern formation, GO:0030154: cell differentiation, GO:0030182: neuron differentiation, GO:0030426: growth cone, GO:0030900: forebrain development, GO:0030900: forebrain development, GO:0030901: midbrain development, GO:0030901: midbrain development, GO:0032525: somite rostral/caudal axis specification, GO:01.54 -1.54
230678_at 230678 128218 Tmem125 transmembrane	protein	125 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process, GO:0016020: membrane, GO:0016021: integral to membrane1.54 -1.54
100124365_at 100124365 Traj24 T	cell	receptor	alpha	joining	24 1.54 -2.25
14985_at 14985 H2-M10.1 histocompatibility	2,	M	region	locus	10.1 GO:0003674:	molecular_function, GO:0005575: cellular_component, GO:0008150: biological_process04144:	E docytosis,	04145: Ph gos e, 04514: Cell adhesion m le ules (CAMs), 04612: Antigen processing and presentation, 04940: Type I	diabetes mellitus, 05320: Autoimmune thyroid disease, 05330: Allograft	rejection, 05332: Graft-versus-host	disease, 05416: Viral myocarditis1.53 -1.74
227627_at 227627 29989 Obp2a odorant	binding	protein	2A GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0005576: extracellular region, GO:0006810: transport, GO:0008150: biological_process1.53 -1.53
258269_at 258269 Olfr930 olfactory	receptor	930 GO:0004984:	olfactory	receptor activity, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactor 	transduction1.52 -1.97
620253_at 620253 Dcpp3 demilune	cell	and	parotid	protein	3 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process1.52 -1.67
56858_at 56858 390442 Olfr749 olfactory	receptor	749 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction1.51 -1.82
628573_at 628573 Gm6897 predicted	pseudogene	6897 1.51 -1.51
84506_at 84506 Hamp hepcidin	antimicrobial	peptide GO:0005179:	hormone	activity,	GO:0005576:	extracellular region, GO:0005737: cytoplasm, GO:0006879: cellular iron ion homeostasis, GO:0006879: cellular iron ion homeostasis, GO:0042742: defense response to bacterium, GO:0045179: apical cortex, GO:0050832: defense response to fungus1.51 5.11
100039707_at 100039707 10588 Gm2382 predicted	gene	2382 GO:0003674:	molecular_function, GO:0005575: cellular_component, GO:0008150: biological_process00670:	O e	carbon	pool by fol te, 01100: Metabolic pathways-1.50 .60
212627_at 212627 5636 Prpsap2 phosphoribosyl	pyrophosphate	synthetase-associated	protein	2 GO:0000287:	magnesium	ion	binding,	GO:0002189: ribose phosphate diphosphokinase complex, GO:0003674: molecular_function, GO:0004749: ribose phosphate diphosphokinase activity, GO:0008150: biological_process, GO:0009165: nucleotide biosynthetic process, GO:0043234: protein complex-1.51 1.97
235956_at 235956 Zfp825 zinc	finger	protein	825 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process, GO:0046872: metal ion binding-1.52 1.59
258626_at 258626 Olfr1501 olfactory	receptor	1501 GO:0004871:	signal	transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactory	transduction-1.53 1.53
11287_at 11287 Pzp pregnancy	zone	protein GO:0004866:	endopeptidase	inhibitor	activity,	GO:0004867: serine-type endopeptidase inhibitor activity, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0010466: negative regulation of peptidase activity, GO:0030414: peptidase inhibitor activity, GO:0032403: protein complex binding-1.55 4.75
353234_at 353234 56146 Pcdha2 protocadherin	alpha	2 GO:0003674:	molecular_function,	GO:0005634: nucleus, GO:0005783: endoplasmic reticulum, GO:0008150: biological_process-1.55 -1.55
74149_at 74149 Zfp946 zinc	finger	protein	946 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process, GO:0046872: metal ion binding-1.56 1.56
17842_at 17842 Mup3 major	urinary	protein	3 GO:0005215:	transporter	activity,	GO:0005550: pheromone binding, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0006810: transport, GO:0036094: small molecule binding-1.57 6.37
14161_at 14161 2243 Fga fibrinogen	alpha	chain GO:0005615:	extracellular space, GO:0005938: cell cortex, GO:0007596: blood coagulation, GO:0009897: external side of plasma	membrane, GO:0031091: platelet	alpha	granule, GO:0043499: eukaryotic cell surface binding, GO:0051592: response to calcium ion, GO:0072562: blood microparticle04610:	Complement	and coagulation cascades-1.57 2.63
111186_at 111186 Stmn1-rs1 stathmin	1,	related	sequence	1 -1.61 1.61
76220_at 76220 6530402F18Rik RIKEN	cDNA	6530402F18	gene -1.62 1.92
50887_at 50887 Hmgn5 high-mobility	group	nucleosome	binding	domain	5 GO:0000785:	chromatin,	GO:0003677:	DNA	binding, GO:0003682: chromatin binding, GO:0005634: nucleus, GO:0005654: nucleoplasm, GO:0005730: nucleolus, GO:0006351: transcription, DNA-dependent, GO:0006355: regulation of transcription, DNA-dependent, GO:0006357: regulation of transcription from RNA polymerase II	promoter, GO:0016568: chromatin modification, GO:0031492: nucleosomal DNA binding, GO:0043231: intracellular membrane-bounded organelle-1.62 1.62
223337_at 223337 133688 Ugt3a2 UDP	glycosyltransferases	3	family,	polypeptide	A2 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process, GO:0008152: metabolic process, GO:0015020: glucuronosyltransferase activity, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0016740: transferase activity, GO:0016757: transferase activity, transferring glycosyl groups, GO:0016758: transferase activity, transferring hexosyl groups-1.62 3.78
100503921_at 100503921 Gm19966 predicted	gene,	19966 -1.63 1.56
56312_at 56312 26471 Nupr1 nuclear	protein	1 GO:0002526:	acute	inflammatory	response,	GO:0003682: chromatin binding, GO:0005515: protein binding, GO:0005622: intracellular, GO:0005634: nucleus, GO:0006461: protein complex assembly, GO:0006473: protein acetylation, GO:0008584: male gonad development, GO:0009636: response to toxin, GO:0016049: cell growth, GO:0031401: positive regulation of protein modification process, GO:0035914: skeletal muscle cell differentiation, GO:0042771: DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis, GO:0043065: positive regulation of apoptotic process, GO:0045786: negative regulation of cell cycle, GO:0048147: negative regulation of fibroblast	proliferation, GO:2000194: regulation of female gonad development-1.64 1.64
14473_at 14473 2638 Gc group	specific	component GO:0003779:	actin	binding,	GO:0005499:	vitamin D binding, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0005829: cytosol, GO:0006810: transport, GO:0030424: axon, GO:0042359: vitamin D metabolic process, GO:0048471: perinuclear region of cytoplasm, GO:0051180: vitamin transport, GO:0051183: vitamin transporter activity, GO:0055085: transmembrane transport-1.64 7.21
110135_at 110135 2244 Fgb fibrinogen	beta	chain GO:0005102:	receptor	binding, GO:0005576: extracellular region, GO:0005577: fibrinogen complex, GO:0005615: extracellular space, GO:0005938: cell cortex, GO:0007165: signal transduction, GO:0007596: blood coagulation, GO:0007599: hemostasis, GO:0009897: external side of plasma	membrane, GO:0030168: platelet	activation, GO:0030674: protein binding, bridging, GO:0031091: platelet	alpha	granule, GO:0043499: eukaryotic cell surface binding, GO:0051087: chaperone binding, GO:0051258: protein polymerization, GO:0051592: response to calcium ion, GO:0072562: blood microparticle04610:	Complement	and coagulation cascades-1.65 4.39
100502708_at 100502708 Gm19333 predicted	gene,	19333 -1.65 1.97
268697_at 268697 891 Ccnb1 cyclin	B1 GO:0000079:	regulation of cyclin-dependent	protein kinase activity, GO:0000236: mitotic prometaphase, GO:0000922: spindle pole, GO:0000942: condensed nuclear chromosome outer kinetochore, GO:0001556: oocyte maturation, GO:0001701: in utero embryonic development, GO:0001933: negative regulation of protein phosphorylation, GO:0005113: patched binding, GO:0005515: protein binding, GO:0005634: nucleus, GO:0005634: nucleus, GO:0005737: cytoplasm, GO:0005813: centrosome, GO:0005856: cytoskeleton, GO:0006461: protein complex assembly, GO:0006468: protein phosphorylation, GO:0007049: cell cycle, GO:0007067: mitosis, GO:0007080: mitotic metaphase plate congression, GO:0010629: negative regulation of gene expression, GO:0016020: membrane, GO:0016301: kinase activity, GO:0016572: histone phosphorylation, GO:0019901: protein kinase binding, GO:0031442: positive regulation of mRNA 3'-end processing, GO:0032403: protein complex binding, GO:0033129: positive regulation of histone phosphorylation, GO:0035173: histone kinase04110:	Cell	cycle,	04114: Oocyte m iosis, 04115: p53 signaling pathway, 04914: Progesterone-mediated oocyte maturation-1.65 1.67
100124355_at 100124355 Traj34 T	cell	receptor	alpha	joining	34 -1.66 1.79
100316865_at 100316865 Gm10931 predicted	gene	10931 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-1.66 2.02
17220_at 17220 4176 Mcm7 minichromosome	maintenance	deficient	7	(S.	cerevisiae) GO:0000166:	nucleotide binding, GO:0003677: DNA binding, GO:0003678: DNA helicase activity, GO:0003697: single-stranded DNA binding, GO:0004386: helicase activity, GO:0005515: protein binding, GO:0005524: ATP binding, GO:0005634: nucleus, GO:0005634: nucleus, GO:0005829: cytosol, GO:0006260: DNA replication, GO:0006268: DNA unwinding involved in replication, GO:0006270: DNA-dependent	DNA replication initiation, GO:0006974: response to DNA damage stimulus, GO:0007049: cell cycle, GO:0008283: cell proliferation, GO:0016787: hydrolase activity, GO:0017111: nucleoside-triphosphatase activity, GO:0042325: regulation of phosphorylation, GO:0042555: MCM	complex03030:	DNA	replication, 04110: Cell cycle-1.67 1.99
22242_at 22242 7369 Umod uromodulin GO:0000922:	spindle	pole,	GO:0005509:	calcium ion binding, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0005794: Golgi apparatus, GO:0005886: plasma	membrane, GO:0007588: excretion, GO:0016020: membrane, GO:0016323: basolateral plasma	membrane, GO:0016324: apical plasma	membrane, GO:0016324: apical plasma	membrane, GO:0016324: apical plasma	membrane, GO:0031225: anchored to membrane, GO:0031410: cytoplasmic vesicle, GO:0042995: cell projection, GO:0045121: membrane raft, GO:0045177: apical part	of cell, GO:0048878: chemical homeostasis, GO:0072372: primary cilium, GO:2000021: regulation of ion homeostasis-1.69 1.69
13095_at 13095 1558 Cyp2c29 cytochrome	P450,	family	2,	subfamily	c,	polypeptide	29 GO:0004497:	monooxygenase activity, GO:0005506: iron ion binding, GO:0005783: endoplasmic reticulum, GO:0006082: organic acid metabolic process, GO:0009055: electron carrier activity, GO:0016020: membrane, GO:0016491: oxidoreductase activity, GO:0016705: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, GO:0016712: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen, GO:0017144: drug metabolic process, GO:0020037: heme binding, GO:0034875: caffeine oxidase activity, GO:0042738: exogenous drug catabolic process, GO:0043231: intracellular membrane-bounded organelle, GO:0046872: metal ion binding, GO:0055114: oxidation-reduction process, GO:0070330: aromatase activity, GO:0070989: oxidative demethylation00590:	Arachidonic	acid metab lism, 00591: Linoleic acid metab lism, 00830: Retinol metabolism, 00980: Metabolism of xenobiotics by cytochrome P450, 00982: Drug metabolism - cytochrom P45 , 01100: Metabolic pathways-1.69 6.55
15387_at 15387 3190 Hnrnpk heterogeneous	nuclear	ribonucleoprotein	K GO:0000790:	nuclear	chromatin, GO:0000978: RNA polymerase II	core promoter proximal region sequence-specific DNA binding, GO:0001077: RNA polymerase II	core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, GO:0003676: nucleic acid binding, GO:0003677: DNA binding, GO:0003697: single-stranded DNA binding, GO:0003723: RNA binding, GO:0005515: protein binding, GO:0005634: nucleus, GO:0005681: spliceosomal complex, GO:0005737: cytoplasm, GO:0006397: mRNA processing, GO:0008380: RNA splicing, GO:0010988: regulation of low-density lipoprotein particle clearance, GO:0030529: ribonucleoprotein complex, GO:0045716: positive regulation of low-density lipoprotein particle receptor biosynthetic process, GO:0045944: positive regulation of transcription from RNA polymerase II	promoter, GO:0048260: positive regulation of receptor-mediated endocytosis, GO:0071013: catalytic step 2 spliceosome, GO:0072369: regulation of lipid transport	by po03040:	Spliceosome -1.70 1.70
69282_at 69282 1700001J03Rik RIKEN	cDNA	1700001J03	gene GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-1.71 2.55
69354_at 69354 55089 Slc38a4 solute	carrier	family	38,	member	4 GO:0003333:	amino	acid	transmembrane	transport, GO:0005886: plasma	membrane, GO:0006810: transport, GO:0006811: ion transport, GO:0006814: sodium ion transport, GO:0006865: amino acid transport, GO:0015171: amino acid transmembrane transporter activity, GO:0015293: symporter activity, GO:0015837: amine transport, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0055085: transmembrane transport-1.72 2.70
74155_at 74155 54206 Errfi1 ERBB	receptor	feedback	inhibitor	1 GO:0005515:	protein	binding,	GO:0005634:	nucleus, GO:0005737: cytoplasm, GO:0005737: cytoplasm, GO:0005829: cytosol, GO:0005886: plasma	membrane, GO:0007175: negative regulation of epidermal growth factor-activated receptor activity, GO:0007175: negative regulation of epidermal growth factor-activated receptor activity, GO:0016020: membrane, GO:0019900: kinase binding, GO:0019901: protein kinase binding, GO:0031098: stress-activated protein kinase signaling cascade, GO:0031234: extrinsic to internal side of plasma	membrane, GO:0031953: negative regulation of protein autophosphorylation, GO:0042059: negative regulation of epidermal growth factor receptor signaling pathway, GO:0043589: skin morphogenesis, GO:0045616: regulation of keratinocyte differentiation, GO:0048286: lung alveolus development, GO:0050732: negative regulation of peptidyl-tyrosine phosphorylation, GO:0060426: lung vasculature development, GO:0060428: lung epithelium development-1.73 1.63
258745_at 258745 Olfr689 olfactory	receptor	689 GO:0004984:	olfactory	receptor activity, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell04740:	Olfactor 	transduction-1.74 -2.16
72263_at 72263 1700030F04Rik RIKEN	cDNA	1700030F04	gene -1.74 1.82
15439_at 15439 3240 Hp haptoglobin GO:0001889:	liver	development,	GO:0003824: catalytic activity, GO:0004252: serine-type endopeptidase activity, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0005783: endoplasmic reticulum, GO:0005794: Golgi apparatus, GO:0006508: proteolysis, GO:0010942: positive regulation of cell death, GO:0030492: hemoglobin binding, GO:0031838: haptoglobin-hemoglobin complex, GO:0042542: response to hydrogen peroxide, GO:0042803: protein homodimerization activity, GO:0051354: negative regulation of oxidoreductase activity, GO:2000296: negative regulation of hydrogen peroxide catabolic process-1.74 4.26
15007_at 15007 3105 H2-Q10 histocompatibility	2,	Q	region	locus	10 GO:0002474:	antigen	processing and presentation of peptide antigen via	MHC class I, GO:0006955: immune response, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0019882: antigen processing and presentation, GO:0042612: MHC class I	protein complex04144:	Endocytosis,	04145: Phagosome, 04514: Cell adhesion molecules (CAMs), 04612: Antigen processing and prese tation, 4940: Type I	diabetes ellitus, 0532 : Autoimmune thyroid dise se, 05330: All graft	rejection, 05332: Graft-versus-h st	disease, 05416: Viral myocarditis-1.74 4.22
622402_at 622402 Akr1c12 aldo-keto	reductase	family	1,	member	C12 GO:0004033:	aldo-keto	reductase	(NADP)	activity, GO:0005575: cellular_component, GO:0006805: xenobiotic metabolic process-1.75 3.26
15458_at 15458 3263 Hpx hemopexin GO:0002639:	positive	regulation	of	immunoglobulin production, GO:0002925: positive regulation of humoral immune response mediated by circulating immunoglobulin, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0006810: transport, GO:0020027: hemoglobin metabolic process, GO:0020037: heme binding, GO:0042168: heme metabolic process, GO:0042511: positive regulation of tyrosine phosphorylation of Stat1 protein, GO:0046872: metal ion binding, GO:0051246: regulation of protein metabolic process, GO:0060332: positive regulation of response to interferon-gamma, GO:0060335: positive regulation of interferon-gamma-mediated signaling pathway-1.77 3.72
100861643_at 100861643 LOC100861643 uncharacterized	LOC100861643 -1.77 1.64
14963_at 14963 3105 H2-Bl histocompatibility	2,	blastocyst GO:0005737:	cytoplasm, GO:0005886: plasma	membrane, GO:0009986: cell surface, GO:0016021: integral to membrane, GO:0042270: protection from natural killer cell mediated cytotoxicity04144:	Endocytosis,	04145: Phagosome, 4514: Cell adhesion molecules (CAMs), 04612: Antige processing and es n ation, 04940: Type I	diabetes mellitus, 05320: Autoimmune thyroid disease, 05330: Allograft	rejection, 05332: Graft-versus-host	disease, 05416: Viral myocarditis-1.78 1.52
667034_at 667034 4860 Pnp2 purine-nucleoside	phosphorylase	2 GO:0003674:	molecular_function, GO:0005575: cellular_component, GO:0008150: biological_process00230:	Purine	metabolism, 00240: Pyrimidi e metabolism, 00760: Nicotinat and nicotinamide metabolism, 01100: Metabolic pathways-1.78 1.78
12045_at 12045 597 Bcl2a1b B	cell	leukemia/lymphoma	2	related	protein	A1b GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-1.80 2.38
666914_at 666914 Gm8359 predicted	gene	8359 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-1.80 1.73
13109_at 13109 Cyp2j5 cytochrome	P450,	family	2,	subfamily	j,	polypeptide	5 GO:0004497:	monooxygenase activity, GO:0005506: iron ion binding, GO:0005783: endoplasmic reticulum, GO:0009055: electron carrier activity, GO:0016020: membrane, GO:0016491: oxidoreductase activity, GO:0016705: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, GO:0016712: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen, GO:0020037: heme binding, GO:0043231: intracellular membrane-bounded organelle, GO:0046872: metal ion binding, GO:0055114: oxidation-reduction process, GO:0070330: aromatase activity00590:	Arachidonic	acid metab lism, 00591: Linoleic acid metab lism, 01100: Metabolic pathways-1.80 4.06
230161_at 230161 Acnat1 acyl-coenzyme	A	amino	acid	N-acyltransferase	1 GO:0005777:	peroxisome,	GO:0006629:	lipid	metabolic process, GO:0006631: fatty acid metabolic process, GO:0006637: acyl-CoA metabolic process, GO:0016290: palmitoyl-CoA hydrolase activity, GO:0016410: N-acyltransferase activity, GO:0016740: transferase activity, GO:0016746: transferase activity, transferring acyl groups, GO:0016790: thiolester hydrolase activity-1.81 5.79
320004_at 320004 A930002H24Rik RIKEN	cDNA	A930002H24	gene GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-1.83 2.15
19946_at 19946 6156 Rpl30 ribosomal	protein	L30 GO:0003674:	molecular_function, GO:0005737: cytoplasm, GO:0022625: cytosolic large ribosomal subunit03010:	Ribosome -1.83 1.83
431706_at 431706 81931 Zfp457 zinc	finger	protein	457 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process, GO:0046872: metal ion binding-1.84 2.21
16612_at 16612 354 Klk1 kallikrein	1 GO:0003824:	catalytic	activity,	GO:0004252:	serine-type endopeptidase activity, GO:0006508: proteolysis, GO:0008233: peptidase activity, GO:0008236: serine-type peptidase activity, GO:0016787: hydrolase activity-1.85 4.81
13096_at 13096 Cyp2c37 cytochrome	P450,	family	2.	subfamily	c,	polypeptide	37 GO:0004497:	monooxygenase activity, GO:0005506: iron ion binding, GO:0005783: endoplasmic reticulum, GO:0009055: electron carrier activity, GO:0016020: membrane, GO:0016491: oxidoreductase activity, GO:0016705: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, GO:0020037: heme binding, GO:0043231: intracellular membrane-bounded organelle, GO:0046872: metal ion binding, GO:0055114: oxidation-reduction process, GO:0070330: aromatase activity00590:	Arachidonic	acid metab lism, 00591: Linoleic acid metab lism, 00830: Retinol metabolism, 00980: Metabolism of xenobiotics by cytoch ome P45 , 00982 Drug metabolism - cy ochrome P450, 01100: Metabolic pathw ys-1.85 3.96
64697_at 64697 Keg1 kidney	expressed	gene	1 GO:0005737:	cytoplasm,	GO:0005739:	mitochondrion, GO:0005813: centrosome, GO:0005856: cytoskeleton, GO:0005874: microtubule, GO:0008152: metabolic process, GO:0016740: transferase activity, GO:0016746: transferase activity, transferring acyl groups, GO:0047961: glycine N-acyltransferase activity-1.85 2.7
18405_at 18405 Orm1 orosomucoid	1 GO:0002682:	regulation	of	immune	system	process, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0006810: transport, GO:0006953: acute-phase response, GO:0008144: drug binding-1.87 3.32
99571_at 99571 2266 Fgg fibrinogen	gamma	chain GO:0005102:	receptor	binding, GO:0005576: extracellular region, GO:0005577: fibrinogen complex, GO:0005615: extracellular space, GO:0005938: cell cortex, GO:0007165: signal transduction, GO:0007596: blood coagulation, GO:0007599: hemostasis, GO:0009897: external side of plasma	membrane, GO:0030168: platelet	activation, GO:0030674: protein binding, bridging, GO:0031091: platelet	alpha	granule, GO:0043499: eukaryotic cell surface binding, GO:0051258: protein polymerization, GO:0051592: response to calcium ion, GO:0072562: blood microparticle04610:	Complement	and coagulation cascades, 51 0: Staphyl coccus aureus infection-1.87 5.13
12350_at 12350 761 Car3 carbonic	anhydrase	3 GO:0004089:	carbonate dehydratase activity, GO:0005737: cytoplasm, GO:0006730: one-carbon metabolic process, GO:0006979: response to oxidative stress, GO:0008270: zinc ion binding, GO:0016151: nickel cation binding, GO:0016829: lyase activity, GO:0046872: metal ion binding00910:	Ni rogen	me abolism-1.87 6.71
67048_at 67048 Vma21 VMA21	vacuolar	H+-ATPase	homolog	(S.	cerevisiae) GO:0005764:	lysosome,	GO:0005783:	endoplasmic reticulum, GO:0005789: endoplasmic reticulum membrane, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0030127: COPII	vesicle coat, GO:0031410: cytoplasmic vesicle, GO:0070072: vacuolar proton-transporting V-type ATPase complex assembly-1.87 1.80
12983_at 12983 1439 Csf2rb colony	stimulating	factor	2	receptor,	beta,	low-affinity	(granulocyte-macrophage)GO:0004896:	cytokine	receptor activity, GO:0005515: protein binding, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0019221: cytokine-mediated signaling pathway04060:	Cytokine-cytokine receptor interaction, 04210: Apoptosis, 04630: Jak-STAT signaling p thway- .87 1.87
237320_at 237320 64577 Aldh8a1 aldehyde	dehydrogenase	8	family,	member	A1 GO:0001758:	retinal	dehydrogenase	activity,	GO:0001758: retinal dehydrogenase activity, GO:0005622: intracellular, GO:0005737: cytoplasm, GO:0008152: metabolic process, GO:0016491: oxidoreductase activity, GO:0016620: oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor, GO:0042573: retinoic acid metabolic process, GO:0042574: retinal metabolic process, GO:0042574: retinal metabolic process, GO:0042904: 9-cis-retinoic acid biosynthetic process, GO:0055114: oxidation-reduction process-1.90 2.92
100045125_at 100045125 Gm17768 zinc	finger	protein	700-like -1.92 2.04
20044_at 20044 6208 Rps14 ribosomal	protein	S14 GO:0000028:	ribosomal small subunit	assembly, GO:0000122: negative regulation of transcription from RNA polymerase II	promoter, GO:0003735: structural constituent	of ribosome, GO:0005622: intracellular, GO:0005730: nucleolus, GO:0005739: mitochondrion, GO:0005840: ribosome, GO:0006412: translation, GO:0006417: regulation of translation, GO:0022627: cytosolic small ribosomal subunit, GO:0030218: erythrocyte differentiation, GO:0030529: ribonucleoprotein complex, GO:0045182: translation regulator activity, GO:0048027: mRNA 5'-UTR	binding03010:	Ri osome -1.93 2.05
634720_at 634720 Gm11735 predicted	gene	11735 -1.95 1.95
74747_at 74747 54541 Ddit4 DNA-damage-inducible	transcript	4 GO:0001666:	response	to hypoxia, GO:0001666: response to hypoxia, GO:0005622: intracellular, GO:0005737: cytoplasm, GO:0005739: mitochondrion, GO:0006915: apoptotic process, GO:0009968: negative regulation of signal transduction, GO:0032007: negative regulation of TOR	signaling cascade, GO:0043241: protein complex disassembly, GO:0045820: negative regulation of glycolysis, GO:0071889: 14-3-3 protein binding, GO:0072593: reactive oxygen species metabolic process04150:	mTOR	signaling	pathway-2.00 2.32
170741_at 170741 29990 Pilrb1 paired	immunoglobin-like	type	2	receptor	beta	1 GO:0001773:	myeloid	dendritic	cell	activation, GO:0005515: protein binding, GO:0005886: plasma	membrane, GO:0016020: membrane, GO:0016021: integral to membrane, GO:0042288: MHC class I	protein binding, GO:0045671: negative regulation of osteoclast	differentiation-2.04 1.54
666253_at 666253 Gm8005 predicted	gene	8005 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-2.05 1.80
19896_at 19896 4736 Rpl10a ribosomal	protein	L10A GO:0003674:	molecular_function, GO:0005739: mitochondrion, GO:0005840: ribosome, GO:0022625: cytosolic large ribosomal subunit, GO:0030529: ribonucleoprotein complex03010:	Ribosome -2.14 2.06
20704_at 20704 5265 Serpina1e serine	(or	cysteine)	peptidase	inhibitor,	clade	A,	member	1E GO:0004867:	serine-type endopeptidase inhibitor activity, GO:0005576: extracellular region, GO:0010466: negative regulation of peptidase activity, GO:0010951: negative regulation of endopeptidase activity, GO:0030162: regulation of proteolysis, GO:0030414: peptidase inhibitor activity, GO:0034097: response to cytokine stimulus, GO:0043434: response to peptide hormone stimulus04610:	Compleme t	and co gulation cascades-2.16 8. 3
394435_at 394435 54578 Ugt1a6b UDP	glucuronosyltransferase	1	family,	polypeptide	A6B GO:0003674:	molecular_function, GO:0005575: cellular_component, GO:0008150: biological_process00040:	Pentose	and	glucuronate interconversions, 00053: Asc rbate and aldarate metabolism, 00140: Steroid hormone biosynthesis, 00500: Starch and sucrose metabolism, 00514: Other types of O-glycan biosynthesis, 00830: Retinol metabolism, 00860: Porphyrin and chlorophyll metabolism, 00980: Metabolism of xenobiotics by cytochrome P450, 00982: Drug metabolism - cytochrome P450, 00983: Drug metabolism - other enzymes, 01100: Metabolic pathways-2.17 4.57
258220_at 258220 Olfr1148 olfactory	receptor	1148 GO:0004871:	signal	transducer	activity,	GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell-2.17 1.95
64659_at 64659 63931 Mrps14 mitochondrial	ribosomal	protein	S14 GO:0003735:	structural	constituent	of	ribosome, GO:0005622: intracellular, GO:0005739: mitochondrion, GO:0005763: mitochondrial small ribosomal subunit, GO:0005840: ribosome, GO:0006412: translation, GO:0008150: biological_process, GO:0030529: ribonucleoprotein complex-2.19 .81
26458_at 26458 11001 Slc27a2 solute	carrier	family	27	(fatty	acid	transporter),	member	2 GO:0000038:	very	long-chain fatty acid metabolic process, GO:0000166: nucleotide binding, GO:0001561: fatty acid alpha-oxidation, GO:0001676: long-chain fatty acid metabolic process, GO:0001676: long-chain fatty acid metabolic process, GO:0001676: long-chain fatty acid metabolic process, GO:0003824: catalytic activity, GO:0004467: long-chain fatty acid-CoA ligase activity, GO:0004467: long-chain fatty acid-CoA ligase activity, GO:0004467: long-chain fatty acid-CoA ligase activity, GO:0005102: receptor binding, GO:0005524: ATP binding, GO:0005739: mitochondrion, GO:0005777: peroxisome, GO:0005777: peroxisome, GO:0005777: peroxisome, GO:0005777: peroxisome, GO:0005778: peroxisomal membrane, GO:0005779: integral to peroxisomal membrane, GO:0005779: integral to peroxisomal membrane, GO:0005783: endoplasmic reticulum, GO:0005783: endoplasmic reticulum, GO:0005788: endoplasmic reticulum lumen, GO:0005788: endoplasmic reticulum lumen, GO:0005789: endoplasmic reticulum membrane, GO:0006629: lipid metabolic process, G03320:	PPAR	signaling	pathway, 04146: Peroxisome-2.21 .52
22759_at 22759 Zfp97 zinc	finger	protein	97 GO:0003674:	molecular_function,	GO:0005634: nucleus, GO:0008150: biological_process, GO:0046872: metal ion binding-2.26 1.68
544848_at 544848 Gm5784 predicted	gene	5784 GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-2.26 1.87
20211_at 20211 100528017 Saa4 serum	amyloid	A	4 GO:0005576:	extracellular	region,	GO:0006953: acute-phase response, GO:0034364: high-density lipoprotein particle-2.43 5.69
18648_at 18648 5223 Pgam1 phosphoglycerate	mutase	1 GO:0004619:	phosphoglycerate mutase activity, GO:0004619: phosphoglycerate mutase activity, GO:0005634: nucleus, GO:0005829: cytosol, GO:0006110: regulation of glycolysis, GO:0019901: protein kinase binding, GO:0043456: regulation of pentose-phosphate shunt, GO:0045730: respiratory burst00010:	Glycoly is	/	Gluconeogenesis, 01100: Metabolic pathw ys-2.46 2.09
637896_at 637896 Vmn2r78 vomeronasal	2,	receptor	78 GO:0003674:	molecular_function,	GO:0004871: signal transducer activity, GO:0004930: G-protein coupled receptor activity, GO:0005575: cellular_component, GO:0005886: plasma	membrane, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0008150: biological_process, GO:0016020: membrane, GO:0016021: integral to membrane-2.54 3.11
16483_at 16483 Kap kidney	androgen	regulated	protein GO:0005576:	extracellular	region -2.60 3.22
243944_at 243944 4930433I11Rik RIKEN	cDNA	4930433I11	gene GO:0003674:	molecular_function,	GO:0005575: cellular_component, GO:0008150: biological_process-2.66 2.20
20208_at 20208 6288 Saa1 serum	amyloid	A	1 GO:0001664:	G-protein	coupled	receptor	binding, GO:0005515: protein binding, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0006953: acute-phase response, GO:0007204: elevation of cytosolic calcium ion concentration, GO:0008203: cholesterol metabolic process, GO:0034364: high-density lipoprotein particle, GO:0045785: positive regulation of cell adhesion, GO:0048246: macrophage chemotaxis, GO:0048247: lymphocyte chemotaxis, GO:0050715: positive regulation of cytokine secretion-3.06 5.25
723825_at 723825 Mir103-2 microRNA	103-2 GO:0071230:	cellular	response	to	amino	acid	stimulus, GO:0071363: cellular response to growth factor stimulus-3.14 1.9
18406_at 18406 Orm2 orosomucoid	2 GO:0002682:	regulation	of	immune	system	process, GO:0005576: extracellular region, GO:0005615: extracellular space, GO:0006810: transport, GO:0006953: acute-phase response-3.16 3.5
258095_at 258095 Olfr119 olfactory	receptor	119 GO:0004871:	signal	transducer	activity,	GO:0004930: G-protein coupled receptor activity, GO:0004984: olfactory receptor activity, GO:0007165: signal transduction, GO:0007186: G-protein coupled receptor signaling pathway, GO:0007608: sensory perception of smell, GO:0016021: integral to membrane, GO:0050911: detection of chemical stimulus involved in sensory perception of smell-3.60 -2.05
20209_at 20209 6288 Saa2 serum	amyloid	A	2 GO:0005515:	protein	binding,	GO:0005576:	extracellular region, GO:0006953: acute-phase response, GO:0034364: high-density lipoprotein particle-4.63 4.97
